Magneto Therapy in the Therapy of Glaucoma (GME)

NCT02300818 Phase 1/Phase 2 UNKNOWN

Glaucoma is among the leading causes for blindness in the western world. Elevated intraocular pressure (IOP) has been identified as the most important risk factor. However, some patients progress despite adequate IOP lowering while some subjects with elevated IOP never develop glaucoma. Other patients develop glaucoma although IOP measurements were always in the normal range. Therefore, other factors must be involved. In the last years, studies using MRI have been performed and evidence has accumulated that also changes in retrobulbar structures are present, in particular in the lateral geniculate nucleus and the visual cortex. However, these studies were limited by the low spatial resolution of the MRI instruments used.

Details

Lead sponsor	American Society Of Thermalism And Climatology Inc
Phase	Phase 1/Phase 2
Status	UNKNOWN
Enrolment	100
Start date	2014-11
Completion	2016-12

Conditions

• Primary Open Angle Glaucoma
• Hypertension Ocular

Interventions

• Pulsed Electromagnetic Field Therapy
• Seawater eyedrops

Primary outcomes

• Intro-ocular pression after magnetic field exposition — 12 weeks
  Pulsed Electromagnetic Field Therapy

Countries

United States